Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4059-13 in combination with R-MPV for untreated primary CNS lymphoma
jRCT2071230124Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tirabrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Ono Pharmaceutical. Primary endpoint: Safety and tolerability of ONO-4059 + R-MPV. Started May 2024; status: active, not recruiting.
02
Drugs
tirabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on jRCT2071230124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230124.